Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

May 15, 2026

Study Completion Date

June 15, 2028

Conditions
UTUCNAC
Interventions
DRUG

Gemcitabine, Cisplatin

Gemcitabine (1000mg/m²) and cisplatin (70mg/m²). Gemcitabine is used on the 1st and 8th days of a 21 - day cycle, and cisplatin is used on the 2nd day of the cycle. A total of 3 - 4 cycles are carried out.A dose reduction to 60% of the original dose (adjusted to 0.6 times the initial dose) will be implemented if deemed clinically necessary, contingent upon meeting either of the following criteria: 1) occurrence of grade 3 or higher treatment-related adverse events as per CTCAE v5.0 guidelines, or 2) evidence of renal impairment manifested by a ≥40% decline in glomerular filtration rate (GFR) from baseline measurements.

Trial Locations (1)

200433

Changhai hospital, Shanghai

All Listed Sponsors
lead

Changhai Hospital

OTHER